Citations

Clear

3042 citation(s) found for "Kumar, S".

Abstract 2686: Associations between a polygenic risk score and risk of multiple myeloma and its precursor
Clay‐Gilmour, Alyssa , Camp, Nicola J. , Brown, Elizabeth E. , Spinelli, John J. , Wu, Xifeng , Robinson, Dennis P. , Kumar, Shaji , Vachon, Celine M. , Hildebrandt, Michelle A.T. , Ziv, Elad , Hofmann, Jonathan N. , Giles, Graham G. , Bhatti, Parveen , Cozen, Wendy , Norman, Aaron D. , Sinnwell, Jason P. , Rajkumar, S. Vincent , Slager, Susan L. , Vachon, Celine M.

Mayo Clinic

Cancer Research | August 7, 2019 | Volume: 79 | Issue: 13_Supplement | Pages: 2686-2686

10.1158/1538-7445.am2019-2686 Get It

Abstract Genome-wide association studies (GWAS) conducted among populations of European ancestry (EA) have identified 23 common single nucleotide polymorphisms (SNPs) associated with multiple myeloma (MM) risk. We hypothesize that the combination of these SNPs in a polygenic risk score (PRS) is likely to be a strong risk factor for MM. However, it is unclear whether the genetic variation associated with MM susceptibility also predisposes to monoclonal gammopathy of undetermined significance (MGUS). Thus, we calculated a PRS and evaluated the association with risk of MM and its precursor, MGUS. We pooled genotype data for 2434 MM and 3446 controls from ten MM GWAS of individuals of EA within the Interlymph Consortium, for 23 MM risk SNPs identified by prior GWAS. An additional 754 MGUS cases were ascertained from Mayo Clinic and MD Anderson clinical practices. To calculate the PRS, we used the risk estimates corresponding to the 23 SNP associations from the largest published MM GWAS. The log of the odds ratio (OR) for each SNP was multiplied by the respective number of risk alleles and summed to generate a PRS for each individual. The PRS was examined continuously, per one standard deviation (SD), and as quintiles, based on the PRS distribution in the controls. Associations of PRS with MM and MGUS risk were examined separately, using multivariable logistic regression assuming an additive model to assess ORs and 95% confidence intervals adjusted for age, sex, and site. We also evaluated age and sex stratified models. The distribution of sex within MM cases, MGUS cases and controls were each ~60% male and ~40% female. The median age was 61, 66, and 66 years for MM cases, MGUS cases and controls, respectively. PRS ranged from 1.52-4.91, with a median PRS of 3.21 for MM cases, 3.19 for MGUS cases, and 3.05 for controls. PRS was significantly associated with MM risk when assessed continuously (OR=1.19 per SD, p=2.2x10-16) and categorically; compared with the middle quintile (Q3), individuals in the highest quintile (Q5) had a 66% increased MM risk (OR=1.66, p=2.3x10-9) and those in the lowest quintile (Q1) had a 38% decreased MM risk (OR=0.62, p=1.3x10-6). PRS was also significantly associated with MGUS risk (OR=1.19 per SD, p=1.7x10-11); individuals with the highest PRS (Q5) had a 77% increased risk (OR=1.77, p=4.0x10-4) and those with lowest PRS (Q1) had 30% decreased risk (OR=0.70, p=0.04), compared with Q3. When stratified by age and sex, similar associations and trends were found. Using an independent sample of MM / MGUS cases and controls, we showed that a PRS constructed from 23 common genetic variants for MM risk is associated with risk of both MM and MGUS, regardless of age or sex. A future direction of this work is testing associations with PRS and clinical characteristics of the MM cases, as well as differences between MGUS cases that progress and those that do not. Our results suggest that common genetic variation may predispose to MGUS as the precursor to MM. Citation Format: Alyssa I. Clay-Gilmour, Michelle A. Hildebrandt, Nicola J. Camp, Elad Ziv, Elizabeth E. Brown, Jonathan N. Hofmann, John J. Spinelli, Graham G. Giles, Parveen Bhatti, Wendy Cozen, Xifeng Wu, Dennis P. Robinson, Aaron D. Norman, Jason P. Sinnwell, Shaji K. Kumar, S Vincent Rajkumar, Susan L. Slager, Celine M. Vachon. Associations between a polygenic risk score and risk of multiple myeloma and its precursor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2686.
Significance of prolonged PR interval in infections
Mishra, Ajay Kumar , Sahu, Kamal Kant , Lal, Amos , Mishra, Ajay K , Lal, Amos

Mayo Clinic

QJM: An International Journal of Medicine | July 24, 2019 | Volume: 113 | Issue: 2 | Pages: 150-151

10.1093/qjmed/hcz192 | PMID 31359046 Get It

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Denlinger, Crystal S. , Enzinger, Peter C. , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Glasgow, Robert E. , Hayman, James A. , Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Jaroszewski, Dawn E. , Johung, Kimberly L. , Keswani, Rajesh N. , Kleinberg, Lawrence , Leong, Stephen , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Paluri, Ravi Kumar , Park, Haeseong , Poultsides, George A. , Roses, Robert E. , Strong, Vivian E. , Wiesner, Georgia L. , Willett, Christopher G. , Wright, Cameron D., McMillian, Nicole R., Pluchino, Lenora A. , Jaroszewski, Dawn, Ajani, Jaffer A , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Perry, Kyle A. , Pimiento, José M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 855-883

10.6004/jnccn.2019.0033 | PMID 31319389 Get It

Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
Ten‐year survivors in AL amyloidosis: characteristics and treatment pattern
Muchtar, Eli , Gertz, Morie A. , Lacy, Martha Q. , Dingli, David , Grogan, Martha , AbouEzzeddine, Omar F. , Hayman, Suzanne R. , Kapoor, Prashant , Fonder, Amie , Hobbs, Miriam, Hwa, Yi L. , Warsame, Rahma , Kourelis, Taxiarchis , Russell, Stephen J. , Lust, John A., Lin, Yi , Zeldenrust, Steven R., Kyle, Robert A. , Kumar, Shaji , Hwa, Yi Lisa, Gonsalves, Wilson , Kourelis, Taxiarchis V, Russell, Stephen, Zeldenrust, Steven, Kumar, Shaji K , Dispenzieri, Angela , Gertz, Morie A , Muchtar, E , Russell, Stephen J , Dingli, David , Lin, Yi , Go, Ronald S. , Buadi, Francis K. , Leung, Nelson , Gonsalves, Wilson I. , Rajkumar, S. Vincent , Dispenzieri, Angela , AbouEzzeddine, Omar F

Mayo Clinic

British Journal of Haematology | July 12, 2019 | Volume: 187 | Issue: 5 | Pages: 588-594

10.1111/bjh.16096 | PMID 31298751 Get It

Summary Improvement in survival in Light chain (AL) amyloidosis has been seen over recent decades, enabling more patients to achieve long‐term survival. Patients with AL amyloidosis who survived ≥10 years from time of diagnosis ( n = 186) were the subject of this study. Ten‐year survivors represented 22% of the total population. These patients were characterized by favourable patient, organ and plasma cell features. Of note, trisomies were less common among 10‐year survivors compared to those who did not survive to 10 years. All‐time best haematological response was complete response in 67%, very good partial response in 30%, partial response in 2% and no response in 1%, with 11% having received a consolidative strategy for inadequate response to first line therapy. The overall organ response rate to first‐line therapy was 76%, which increased to 86% when considering subsequent line(s) of therapy. Forty‐seven percent of the 10‐year survivors did not require a second‐line therapy. The median treatment‐free survival (TFS) among the 10‐year survivors was 10·5 years (interquartile range 7·4‐12·2). On multivariate analysis independent predictors for TFS were the achievement of complete haematological response and lack of cardiac involvement. Long‐term survivors are increasingly seen in AL amyloidosis and present distinct patient, organ and clonal disease features.
Multidetector CT Findings in the Abdomen and Pelvis after Damage Control Surgery for Acute Traumatic Injuries
Alexander, Lauren F. , LeGout, Jordan D. , Roda, Manohar, Cernigliaro, Joseph G. , Harri, Peter A., Hanna, Tarek N, Roda, Manohar S, Mittal, Pardeep K, Alexander, Lauren F , Hanna, Tarek N , Mittal, Pardeep Kumar

Mayo Clinic

RadioGraphics | July 8, 2019 | Volume: 39 | Issue: 4 | Pages: 1183-1202

10.1148/rg.2019180153 | PMID 31283454 Get It

Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis
Saleh, Abdullah S. Al , Sidiqi, M Hasib , Sidana, Surbhi , Muchtar, Eli , Dingli, David , Lacy, Martha Q. , Warsame, Rahma , Gonsalves, Wilson I. , Kourelis, Taxiarchis , Hayman, Suzanne R. , Kapoor, Prashant , Kumar, Shaji , Al Saleh, Abdullah S , Dispenzieri, Angela , Warsame, Rahma , Gonsalves, Wilson , Kourelis, Taxiarchis , Wolf, Robert C, Gertz, Morie A , Muchtar, E , Sidiqi, M Hasib , Sidana, Surbhi , Dingli, David , Dispenzieri, Angela , Hogan, William J. , Wolf, Robert Christian , Buadi, Francis K. , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | July 5, 2019 | Volume: 94 | Issue: 10 | Pages: 1066-1071

10.1002/ajh.25572 | PMID 31273808 Get It

AbstractThe role of consolidation post autologous stem cell transplant in light chain amyloidosis is not well defined. We retrospectively identified patients who had light chain amyloidosis and underwent autologous stem cell transplant at the Mayo Clinic. Consolidation was defined as any treatment given after the day 100 evaluation post‐transplant to maintain or deepen the response. We identified 471 patients, of whom 72 (15%) received consolidation. Patients receiving consolidation had more advanced disease (Mayo 2012 stage ≥II in 67% vs 52%, P = .02), and had lower day 100 response rates (very good partial response or better: 35% vs 84%, P < .001). After consolidation, rates of very good partial response improved from 24% to 28%, and rates of complete response improved from 11% to 40%. Patients with less than very good partial response who received consolidation, had better progression‐free survival (median of 22.4 vs 8.8 months, P < .001), and the benefit was greater in those who deepened their response (median of 41 vs 8.8 months, P < .001). In patients with less than very good partial response, there was a trend for better overall survival in patients who responded to consolidation (median of 125.8 vs 74.4 months, P = .07). In patients who achieved very good partial response, or better, at day 100 post autologous stem cell transplant, consolidation did not improve progression‐free or overall survival. Consolidation after autologous stem cell transplant for light chain amyloidosis improves progression‐free survival for patients who achieve less than very good partial response.
Faculty Opinions recommendation of Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis.
Kumar, Rajiv

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | July 3, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736021196.793561734 Get It

Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization
Khan, Safi U. , Arora, Shilpkumar , Kumar, Varun , Naraparaju, Vamsidhar , Lahewala, Sopan , Sharma, Purnima , Jain, Varun , Shah, Mahek , Ram, Pradhum , Deshmukh, Abhishek , Khan, Safi , Kumar, Varun , Tripathi, Byomesh , Atti, Varunsiri , Patel, Brijesh D.

Mayo Clinic

Journal of Arrhythmia | June 29, 2019 | Volume: 35 | Issue: 4 | Pages: 612-625

10.1002/joa3.12215 | PMID 31410232 Get It

AbstractBackgroundHypertrophic cardiomyopathy (HCM) accounts for significant morbidity and mortality worldwide. Arrhythmias are considered the main cause of mortality, however, there is paucity of data relating to trends of arrhythmia and associated outcomes in HCM patients.MethodsNationwide Inpatient Sample from 2003 to 2014 was analyzed. HCM related hospitalizations were identified using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD9‐CM) code 425.1 and 425.11 in all diagnosis fields.ResultsOverall, there was an increase in number of hospitalizations related to arrhythmias among HCM patients from 7784 in 2003 to 8380 in 2014 (relative increase 10.5%, P < 0.001). The increase was most significant in patients ≥ 80 years and those with higher comorbidity burden. Atrial fibrillation (AF) was the most frequently occurring arrhythmia however atrial flutter (AFL) witnessed the highest rise during the study period. In general, there was a down trend in mortality with the greatest reduction occurring in patients with ventricular fibrillation/flutter (VF/VFL). The mean length of stay was higher if patients had arrhythmia, which led to increased cost of care from $16105 in 2003 to $19310 in 2014 (relative increase 22.9%, P < 0.001).ConclusionThere is overall decline in HCM related hospitalizations but rise in hospitalization among HCM patients with arrhythmias. HCM with arrhythmia accounts for significant inpatient mortality coupled with prolonged hospital stay and increased cost of care. However, there is an encouraging downtrend in the mortality most likely because of improved clinical practice, cardiac screening and primary and secondary prevention strategies.
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
Sidana, Surbhi , Sidiqi, M Hasib , Lacy, Martha Q. , Muchtar, Eli , Dingli, David , Hayman, Suzanne R. , Gonsalves, Wilson I. , Kapoor, Prashant , Warsame, Rahma , Kourelis, Taxiarchis , Kumar, Shaji , Dispenzieri, Angela , Gonsalves, Wilson , Leung, Nelson , Warsame, Rahma , Kourelis, Taxiarchis , Wolf, Robert C, Gertz, Morie A , Muchtar, E , Sidiqi, M Hasib , Sidana, Surbhi , Dingli, David , Dispenzieri, Angela , Buadi, Francis K. , Leung, Nelson , Wolf, Robert Christian , Hogan, William J. , Gertz, Morie A.

Mayo Clinic

American Journal of Hematology | June 29, 2019 | Volume: 94 | Issue: 9 | Pages: 1020-1026

10.1002/ajh.25566 | PMID 31254301 Get It

Abstract In appropriately selected patients with AL amyloidosis, autologous stem cell transplant (ASCT) is an established treatment modality with excellent outcomes and decreasing transplant related mortality (TRM) over time. We report on 15‐year overall survival (OS) in 159 patients undergoing ASCT from 1996 to 2003, with median follow up of 17.1 years. Day 100 TRM was 13.2% (n = 21). The OS of ≥15 years was observed in 30% (47/159) of patients. Patients surviving ≥15 years were younger (53 vs 56 years, P = .02), less likely to have lambda as the involved light chain (62% vs 78%, P = .03) and were less likely to have heart involvement (32% vs 56%, P = .005). Median OS of patients with heart involvement vs not was 4.0 vs 11.1 years, P = .006 and actuarial 15‐year OS was 23% vs 43%, respectively. A higher proportion of patients with OS ≥15 years received full‐dose melphalan conditioning (81% vs 61%, P = .01), and achieved day 100 complete response (CR) (64% vs 24%, P < .001). Median OS amongst patients who achieved CR vs not was 19.3 vs 5.4 years, P < .001. Heart involvement, receiving full‐dose melphalan and achieving CR remained independent predictors of OS. AL amyloidosis and related complications were the cause of death in 52% of patients overall (1‐5 years post‐transplant: 81%; 5‐10 years: 62% and 10‐15 years: 55%). These results reinforce the key role of ASCT in AL amyloidosis. With improvements in TRM and more options for relapsed disease, we expect the long‐term survival post‐transplant to improve significantly in the future.